News
Press ReleaseRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
Revive Therapeutics is collaborating with Defence R&D Canada to evaluate Bucillamine as a potential treatment for nerve agent exposure, aiming for FDA and Health Canada approvals.
Revive Therapeutics Announces Proposed Shares for Debt Transaction
Revive Therapeutics proposes a shares-for-debt transaction to settle outstanding liabilities, aiming to strengthen its financial position and reduce debt.
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
Revive Therapeutics explores Bucillamine as a cancer therapy with a top U.S. cancer institute, backed by NIH/government funding. Results expected soon.
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
Revive Therapeutics is pleased to announce the voting results for its annual and special meeting of shareholders (the “Meeting”) that was held on Tuesday, March 18, 2025.
Revive Therapeutics Announces Results of Annual Shareholder Meeting
Revive Therapeutics is pleased to announce the voting results for its annual and special meeting of shareholders (the “Meeting”) that was held on Tuesday, March 18, 2025.
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
Revive Therapeutics shares an update on R&D efforts, focusing on Bucillamine for infectious diseases and medical countermeasures. Learn more about their progress.